Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

18.1K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
18.1K
Prodrugs01:30

Prodrugs

3.7K
Prodrugs are a class of pharmaceutical compounds that undergo a biotransformation process within the body to be converted into a pharmacologically active drug. Prodrugs are designed to improve the therapeutic properties of the parent drug, such as enhancing bioavailability, increasing stability, or reducing toxicity. The concept of prodrugs revolves around modifying the chemical structure of the original drug to make it more effective or convenient for administration.
Prodrugs help overcome...
3.7K
Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists01:28

Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists

1.0K
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
1.0K
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

3.5K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
3.5K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

352
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
352
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

2.5K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The mesenteric model of abdominal anatomy.

Nature reviews. Gastroenterology & hepatology·2026
Same author

Polonium-210 as the dominant contributor to the human ingestion dose from Irish farmed oysters (Crassostrea gigas): natural versus artificially derived radioactivity.

Journal of environmental radioactivity·2026
Same author

Unlocking seagrass recovery: a global review for scalable and successful Zostera restoration.

Journal of environmental management·2026
Same author

Making the invisible visible: A global examination of careers and recognition for Imaging Scientists in core facilities.

Journal of microscopy·2026
Same author

Adaptive ER stress promotes mitochondrial remodelling and longevity through PERK-dependent MERCS assembly.

Cell death and differentiation·2025
Same author

Metal(oid)s in Ulva - should we be worried?

Food chemistry·2025

Related Experiment Video

Updated: Dec 16, 2025

Experimental Protocol for Detecting Mitochondrial Function in Hepatocytes Exposed to Organochlorine Pesticides
08:39

Experimental Protocol for Detecting Mitochondrial Function in Hepatocytes Exposed to Organochlorine Pesticides

Published on: September 16, 2020

8.4K

Novel Pt(IV) Prodrugs Displaying Antimitochondrial Effects.

Leila Tabrizi1, Kerry Thompson2, Katarzyna Mnich3

  • 1School of Chemistry, National University of Ireland, Galway H91 TK33, Ireland.

Molecular Pharmaceutics
|July 7, 2020
PubMed
Summary

New platinum(IV) prodrugs targeting the translocator protein (TSPO) show potent anti-cancer activity. Complex C-Pt1 demonstrates a multimodal mechanism, damaging DNA and mitochondria, and increasing reactive oxygen species (ROS).

Keywords:
DNA damagePt(IV) prodrugscisplatincytotoxicityoxaliplatintranslocator protein

More Related Videos

Synthesis and Evaluation of a Ruthenium-based Mitochondrial Calcium Uptake Inhibitor
07:12

Synthesis and Evaluation of a Ruthenium-based Mitochondrial Calcium Uptake Inhibitor

Published on: October 26, 2017

8.1K
Exploring Mitochondrial Energy Metabolism of Single 3D Microtissue Spheroids Using Extracellular Flux Analysis
08:15

Exploring Mitochondrial Energy Metabolism of Single 3D Microtissue Spheroids Using Extracellular Flux Analysis

Published on: February 3, 2022

3.5K

Related Experiment Videos

Last Updated: Dec 16, 2025

Experimental Protocol for Detecting Mitochondrial Function in Hepatocytes Exposed to Organochlorine Pesticides
08:39

Experimental Protocol for Detecting Mitochondrial Function in Hepatocytes Exposed to Organochlorine Pesticides

Published on: September 16, 2020

8.4K
Synthesis and Evaluation of a Ruthenium-based Mitochondrial Calcium Uptake Inhibitor
07:12

Synthesis and Evaluation of a Ruthenium-based Mitochondrial Calcium Uptake Inhibitor

Published on: October 26, 2017

8.1K
Exploring Mitochondrial Energy Metabolism of Single 3D Microtissue Spheroids Using Extracellular Flux Analysis
08:15

Exploring Mitochondrial Energy Metabolism of Single 3D Microtissue Spheroids Using Extracellular Flux Analysis

Published on: February 3, 2022

3.5K

Area of Science:

  • Medicinal Chemistry
  • Cancer Biology
  • Mitochondrial Biology

Background:

  • Platinum(IV) prodrugs offer advantages over platinum(II) drugs like cisplatin.
  • The translocator protein (TSPO) is a potential target in cancer therapy.
  • Quinazolinecarboxamide ligands can be designed to target TSPO.

Purpose of the Study:

  • To design, synthesize, and characterize novel platinum(IV) prodrugs with a TSPO-binding ligand (L3).
  • To evaluate the biological activity, including cytotoxicity and cellular mechanisms, of these new compounds.
  • To compare their efficacy against breast cancer cells with existing platinum drugs and the free ligand.

Main Methods:

  • Synthesis and characterization of platinum(IV) complexes.
  • Cytotoxicity assays in MCF-7 breast cancer and MCF-10A cells.
  • Cellular uptake, ROS generation, DNA damage, and mitochondrial function studies.
  • Molecular docking to investigate ligand-TSPO interactions.

Main Results:

  • The platinum(IV) complex C-Pt1 exhibited the highest efficacy.
  • C-Pt1 demonstrated a multimodal mechanism of action.
  • This mechanism involves DNA damage, significant ROS production, and mitochondrial dysfunction, including loss of membrane potential and morphological changes.

Conclusions:

  • The novel platinum(IV) prodrugs, particularly C-Pt1, show promising anti-cancer potential.
  • Targeting TSPO with platinum(IV) complexes offers a viable strategy for cancer treatment.
  • The multimodal action of C-Pt1 highlights its potential for overcoming drug resistance.